|
Sections
Agriculture
Applied sciences
Arts
Belief
Business
Chronology
Culture
Education
Environment
Geography
Health
History
Humanities
Language
Law
Life
Mathematics
Nature
People
Politics
Science
Society
Technology
|
The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide hormone orexin. There are two variants, OX1 and OX2, each encoded by a different gene (HCRTR1, HCRTR2).[1]
Both orexin receptors exhibit a similar pharmacology - the 2 orexin peptides, orexin-A and orexin-B, bind to both receptors and, in each case, agonist binding results in an increase in intracellular calcium levels. However, orexin-B shows a 10-fold selectivity for orexin receptor type 2, whilst orexin-A is equipotent at both receptors.[2]
Several orexin receptor antagonists are in development for potential use in sleep disorders.
References [edit]
- ^ Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG (2006). "Orexins in the regulation of the hypothalamic-pituitary-adrenal axis". Pharmacol. Rev. 58 (1): 46–57. doi:10.1124/pr.58.1.4. PMID 16507882.
- ^ Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, Elshourbagy NA, Ellis CE, Middlemiss DN, Brown F (September 1999). "Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR". Br. J. Pharmacol. 128 (1): 1–3. doi:10.1038/sj.bjp.0702780. PMC 1571615. PMID 10498827.
External links [edit]
|
|
|
Class A:
Rhodopsin like |
|
|
|
|
|
Metabolites and
signaling molecules
|
|
|
|
Peptide
|
|
|
|
Miscellaneous
|
|
|
|
| Class B: Secretin like |
|
|
Class C: Metabotropic
glutamate / pheromone |
|
|
Class F:
Frizzled / Smoothened |
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
|
|
| Cholecystokinin |
|
|
| CRH |
|
|
| Galanin |
|
|
| Ghrelin |
|
|
| GnRH |
|
|
| MCH |
|
|
| Melanocortin |
|
|
| Neuropeptide S |
|
|
| Neuropeptide Y |
|
|
| Neurotensin |
|
|
| Orexin |
|
|
| Oxytocin |
|
|
| Tachykinin |
|
|
- Agonists: Substance P
Antagonists: Aprepitant
- Befetupitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- FK-888
- Fosaprepitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium
- Orvepitant
- RP-67,580
- SDZ NKT 343
- Vestipitant
- Vofopitant
|
|
|
|
|
|
|
|
|
|
|
| Vasopressin |
|
|
This article incorporates text from the public domain Pfam and InterPro IPR004060
| |
NASDAQ
Tue, 28 May 2013 15:34:13 -0700
Approval would make suvorexant the first orexin receptor antagonist to reach the market. However, we note that the insomnia market is highly competitive and genericized especially given the presence of generic versions of Sanofi's ( SNY ) Ambien.
|  KLEW |
Clinical Psychiatry News Digital Network
Thu, 23 May 2013 08:10:13 -0700
If approved, suvorexant, an orexin receptor antagonist, would be the first drug in this class to be approved for insomnia. The FDA usually follows the recommendations of its advisory panels. The manufacturer, Merck Research Laboratories, studied the ...
|
Oops, we seem to be having trouble contacting Twitter
|
|
You can talk about Orexin receptor with people all over the world in our discussions.
|